Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

Abstract Background Immune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune responses and increase the effectiveness of immunotherapy. However, the eff...

Full description

Bibliographic Details
Main Authors: Jinyu Meng, Jin Peng, Jie Feng, Jochen Maurer, Xiao Li, Yan Li, Shu Yao, Ran Chu, Xiyu Pan, Junting Li, Ting Zhang, Lu Liu, Qing Zhang, Zeng Yuan, Hualei Bu, Kun Song, Beihua Kong
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Journal of Translational Medicine
Subjects:
Ovarian cancer
Niraparib
PARP inhibitors
PD-L1
cGAS/STING pathway
Online Access:https://doi.org/10.1186/s12967-021-03073-0

Internet

https://doi.org/10.1186/s12967-021-03073-0

Similar Items